Feasibility of accelerated whole-breast radiation in the treatment of patients with ductal carcinoma in situ of the breast

Clinical Breast Cancer

Volumn 8, Issue 3, 2008, Pages 269-274

  Constantine, Claire ^a   Parhar, Preeti ^a   Lymberis, Stella ^a   Fenton Kerimian, Maria ^a   Han, Stephanie C ^b   Rosenstein, Barry S ^a   Formenti, Silvia C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Maimonides Cancer Center   (United States)

Author keywords

Breast telangiectasia; Conservation surgery; Cosmesis; Hypofractionation

Indexed keywords

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BREAST FIBROSIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL TRIAL; EDEMA; ESTHETICS; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERPIGMENTATION; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTECTOMY; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 46949103545     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.031     Document Type: Article

References (33)

1. Baxter NN, Virnig BA, Durham SB, et al. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004; 96:443-8.
2. Ernster VL, Barclay J, Kerlikowske K, et al. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996; 275:913-8.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
4. Joslyn SA. Ductal carcinoma in situ: trends in geographic, temporal, and demographic patterns of care and survival. Breast J 2006; 12:20-7.
5. Rosner D, Bedwani RN, Vana J, et al. Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons. Ann Surg 1980; 192:139-47.
6. Vapiwala N, Harris E, Hwang WT, et al. Long-term outcome for mammographically detected ductal carcinoma in situ managed with breast conservation treatment: prognostic significance of reexcision. Cancer J 2006; 12:25-32.
7. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998; 16:441-52.
8. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 2001; 28:400-18.
9. Bijker N, Meijnen E Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853~a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006; 24:3381-7.
10. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003; 362:95-102.
11. Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 2002; 94:1143-50.
12. Barendsen GW Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982; 8:1981-97.
13. Fowler JF The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989; 62:679-94.
14. Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 2006; 7:467-71.
15. Formenti SC, Gidea-Addeo D, Goldberg JD, et al. Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol 2007; 25:2236-42.
16. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events: National Cancer Institute. [Web site]. Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed: June 15, 2002.
17. Gray JR, McCormick B, Cox L, et al. Primary breast irradiation in large-breasted or heavy women: analysis of cosmetic outcome. Int J Radiat Oncol Biol Phys 1991; 21:347-54.
18. Formenti SC, Parhar P, Goldberg JD, et al. Prospective Trial of Individual Optimal Positioning (Prone Versus Supine) for Whole Breast Radiotherapy: Results of the First 168 Patients. Int J Radiat Oncol Biol Phys 2007; 69:S74.
19. Suh WW, Hillner BE, Pierce LJ, et al. Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys 2005; 61:1054-61.
20. Darby SC, McGale P, Taylor CW, et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005; 6:557-65.
21. Marks LB, Yu X, Prosnitz RG, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 2005; 63:214-23.
22. Morrow M. The certainties and the uncertainties of ductal carcinoma in situ. J Natl Cancer Inst 2004; 96:424-5.
23. Solin LJ, Fourquet A, Vicini FA, et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 2005; 103:1137-46.
24. Omlin A, Amichetti M, Azria D, et al. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol 2006; 7:652-6.
25. Antonini N, Jones H, Horiot JC, et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 2007; 82:265-71.
26. Dewar JA, Haviland J, Agarwal RK Hypofractionation for early breast cancer: first results of the UK standardisation of breast radiotherapy (START) trials. J Clin Oncol 2007; 25(18 suppl):7s (Abstract LBA518).
27. Freedman GM, Anderson PR, Goldstein LJ, et al. Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Int J Radiat Oncol Biol Phys 2007; 68:347-53.
28. Deutsch M, Flickinger JC. Patient characteristics and treatment factors affecting cosmesis following lumpectomy and breast irradiation. Am J Clin Oncol 2003; 26:350-3.
29. Fowble B, Fein DA, Hanlon AL, et al. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. Int J Radiat Oncol BiolPhys 1996; 35:669-77.
30. Taylor ME, Perez CA, Halverson KJ, et al. Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys 1995; 31:753-64.
31. Wazer DE, Morr J, Erban JK, et al. The effects of postradiation treatment with tamoxifen on local control and cosmetic outcome in the conservatively treated breast. Cancer 1997; 80:732-40.
32. Collins LC, Schnitt SJ. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol 2005; 18:615-20.
33. Tan EY, Campo L, Han C, et al. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clin Cancer Res 2007; 13:467-74.